Nebraska Children’s Hospital & Medical Center recently published results of their palliative care study utilizing Aeroscena®’s Ascents®-brand clinical aromatherapy inhalers in Cambridge University Press’ journal Palliative and Supportive Care. The team found that the formulas used in the study represented an effective supportive care intervention for pediatric patients experiencing pain, nausea and anxiety. Lead investigator Dr. Meaghann Weaver suggests that this treatment represents a feasible, implementable supportive care intervention for pediatric patients receiving palliative care consults for symptom burden including nausea, pain, and anxiety.
The objective of Dr. Weaver’s study was to investigate the role of aromatherapy in supportive symptom management for pediatric patients receiving palliative care. The research aimed to measure the impact of aromatherapy using validated child-reported nausea, pain, and mood scales 5 minutes and 60 minutes after aromatherapy exposure.
Symptom burden was sequentially assessed at 5 and 60 minutes using the Baxter Retching Faces (BARF) scale for nausea, the Wong-Baker FACES scale for pain, and the Children’s Anxiety and Pain Scale (CAPS) for anxious mood. At 5 minutes, significant improvements were reported for each of the three symptom sets, and remained improved at 60 minutes post-intervention.
Based on the study’s strong, positive results, Dr. Weaver concluded that aromatherapy represents a feasible, implementable supportive care intervention for pediatric patients receiving palliative care consults for symptom burden including nausea, pain and anxiety.
“We could not be more pleased with the outcomes of Dr. Weaver’s study,” said Mark Kohoot, Founder and CEO of Aeroscena. “Knowing that our products are effective in providing comfort care — especially to children — gives us great pride, and we will continue to utilize our unparalleled research platform to further the scientific understanding of phyto-pharmaceuticals for use in clinical environments.”
Aeroscena® LLC, the parent company of Ascents® Clinical Aromatherapy, was founded in 2010 with the mission of making aromatherapy a viable treatment option in clinical environments. The corporate headquarters is located on the campus of the world-renowned Cleveland Clinic, giving the company unparalleled access to some of the greatest medical minds of our time.
Generations of folklore and anecdotal evidence have made aromatherapy popular among millions of people around the world. Despite its popularly-cited effectiveness, aromatherapy has been historically regulated as a cosmetic and thus has received very little attention by the establishment research and medical community. In fact, very little is known about our vast and complex olfactory system.
Aeroscena® is changing this paradigm. They have drawn upon the most credible research available to construct essential oil blends for inhalation. These blends, available for use by professionals and consumers, make no medical claims, as required by the FDA. However, they are actively conducting pilots and clinical trials to be the first company to commercialize essential oil inhalation products as a drug, and its right to make specific medical efficacy claims.
Why aromatherapy? They like it because it can do no harm according to their web site. Their oils are steam distilled, removing the proteins and rendering them completely non-allergenic. They do not pass the blood-brain barrier, and so can not enter the bloodstream. Inhalation is nearly instantaneous, something our nausea relief customers understand, because of its direct connection to the brain.
Their Ascents® clinical aromatherapy formulas are created by health care and aromatherapy experts, then tested and used by many of the world’s leading medical institutions. They work to develop allergen-free, therapeutic scent blends that are economical, simple and safe to use. By applying a rigorous science-based approach to aromatherapy, they assist those experiencing distressing medical symptoms such as anxiety, insomnia, lethargy, and attention deficits to live their healthiest lives.
Lead Research/InvestigatorSource: CISION PR Web